Mobia Medical (NASDAQ:MOBI) Insider Purchases $20,600.00 in Stock

Key Points

• Insider buying: Chase Leavitt purchased 2,000 Mobia Medical shares for $20,600, increasing their direct holdings by 66.67% to 5,000 shares.
• Mixed financial results: Quarterly revenue rose 102.4% year over year to $13.51 million, but the company reported a loss of $1.10 per share, missing estimates of a $0.83 loss.
• Analyst outlook remains positive: Mobia Medical has a consensus “Moderate Buy” rating and an average price target of $20.75, while Citadel Advisors recently acquired 50,000 shares.

Mobia Medical, Inc. (NASDAQ:MOBI - Get Free Report) insider Chase Leavitt acquired 2,000 shares of Mobia Medical stock in a transaction dated Friday, September 11th. The shares were acquired at an average cost of $10.30 per share, with a total value of $20,600.00. Following the completion of the acquisition, the insider directly owned 5,000 shares in the company, valued at $51,500. This trade represents a 66.67% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Mobia Medical Price Performance

Shares of Mobia Medical stock traded up $0.74 during trading on Tuesday, hitting $10.77. 316,997 shares of the company's stock traded hands, compared to its average volume of 154,045. The firm has a market cap of $358.53 million and a P/E ratio of -0.53. The business's fifty day simple moving average is $11.51. Mobia Medical, Inc. has a twelve month low of $9.85 and a twelve month high of $15.29. The company has a current ratio of 13.28, a quick ratio of 12.80 and a debt-to-equity ratio of 0.04.

Mobia Medical (NASDAQ:MOBI - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.27). The business had revenue of $13.51 million for the quarter. The business's quarterly revenue was up 102.4% on a year-over-year basis. As a group, equities research analysts anticipate that Mobia Medical, Inc. will post -2.63 earnings per share for the current year.

Institutional Trading of Mobia Medical

An institutional investor recently bought a new position in Mobia Medical stock. Citadel Advisors LLC bought a new stake in Mobia Medical, Inc. (NASDAQ:MOBI - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 50,000 shares of the company's stock, valued at approximately $670,000. Citadel Advisors LLC owned approximately 0.15% of Mobia Medical as of its most recent filing with the Securities and Exchange Commission (SEC).

Analyst Ratings Changes

Several analysts recently commented on the company. Wall Street Zen raised Mobia Medical from a "sell" rating to a "hold" rating in a research note on Sunday, June 14th. Bank of America started coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set a "buy" rating and a $16.00 price objective for the company. BTIG Research restated a "buy" rating and issued a $19.00 target price on shares of Mobia Medical in a research note on Wednesday, August 12th. The Goldman Sachs Group began coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a "buy" rating and a $31.00 target price on the stock. Finally, Weiss Ratings assumed coverage on shares of Mobia Medical in a research report on Wednesday, August 12th. They set a "sell (e-)" rating for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.